Work

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma

Year: 2026
Type: article
Abstract: Not available.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W7148512588
FWCI:
Cites:
Cited by:
Related to: